Barlo Multiple Sclerosis Program News Today

Tolebrutinib is an Bruton tyrosine kinase (BTK) inhibitor that is being investigated for use in patients who have relapsing multiple sclerosis (MS); investigators presented safety data from a long-term extension study of the phase 2b dose-finding trial.

Among patients with multiple sclerosis receiving assisted reproductive therapy, risk for relapse is increased only in those not treated with disease modifying therapy, new research suggests.

Multiple sclerosis has affected millions of people worldwide. But a new Harvard study has provided compelling evidence that it’s triggered in part by the Epstein-Barr virus.